Sunosi (Solriamfetol HCl) Patent Expiration, LOE Window & CMS Spending

Sunosi (Solriamfetol HCl) by Axsome Malta: FDA Orange Book core substance LOE 2038-11-01 (last listed 2042-12-30), 3 AB generics, $33.9M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAxsome Malta
FDA Application & PathwayN211230 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-11-01
Last Listed Patent or Exclusivity Date2042-12-30
Orange Book Patents (*PED Extensions)42 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$33.9M
2024 Medicare Part D Spend$21.0M
2024 Medicaid Spend$12.9M
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 24.7% 2-yr change)